Table 2 Clinical and laboratory data of COVID-19 patients
From: Altered expression of serum lncRNA CASC2 and miRNA-21-5p in COVID-19 patients
Variables | COVID-19 cases (N = 51) |  |
|---|---|---|
GCS (mean ± SD) | 14.11 | 2.51 |
Duration of admission (days) (mean ± SD) | 9.2 | 5.56 |
ICU admission (n, %) | ||
No | 18 | 35.3% |
Yes | 33 | 64.7% |
DM (n, %) | ||
No | 11 | 21.6% |
Yes | 40 | 78.4% |
Hypertension (n, %) | ||
No | 26 | 51.0% |
Yes | 25 | 49.0% |
Chronic heart disease (n, %) | ||
No | 48 | 94.1% |
Yes | 3 | 5.9% |
Chronic kidney disease (n, %) | ||
CKD on HD | 3 | 5.9% |
No | 48 | 94.1% |
Temperature (mean ± SD) | 37.26 | 0.68 |
Respiratory rate (mean ± SD) | 29.39 | 7.89 |
Heart rate (mean ± SD) | 91.82 | 24.72 |
PH (mean ± SD) | 7.32 | 0.16 |
PCO2 (mean ± SD) | 40.15 | 12.52 |
PO2 (mean ± SD) | 54.4 | 23.88 |
HCO3 (mean ± SD) | 20.59 | 6.11 |
S. Na (mean ± SD) | 139.98 | 8.87 |
S. K (mean ± SD) | 4.11 | 1.16 |
O2 on RA (mean ± SD) | 83.82 | 7.56 |
O2 on oxygen (mean ± SD) | 94.22 | 4.73 |
Ventilation (n, %) | ||
PEEP | 11 | 21.6% |
Mask | 19 | 37.3% |
CPAP | 4 | 7.8% |
Mechanical | 17 | 33.3% |
GGO (n, %) | ||
Yes | 45 | 88.2% |
No | 6 | 11.8% |
Peripheral patches (n, %) | ||
Yes | 5 | 9.8% |
No | 46 | 90.2% |
Treatment (n, %) | ||
Ivermectin | ||
No | 46 | 90.2% |
Yes | 5 | 9.8% |
Remedesevir | ||
No | 36 | 70.6% |
Yes | 15 | 29.4% |
Favipiravir | ||
No | 50 | 98.0% |
Yes | 1 | 2.0% |
Ribavirin | ||
No | 50 | 98.0% |
Yes | 1 | 2.0% |
First PCR (n, %) | ||
Negative | 9 | 17.6% |
Positive | 42 | 82.4% |
CO-RADS (mean ± SD) | 4.54 | 0.73 |
RSNA (n, %) | ||
Atypical | 1 | 2.0% |
Undetermined | 7 | 13.7% |
Typical | 42 | 82.4% |
Percentage of GGO (mean ± SD) | 46.87 | 17.45 |
Number of lobes affected (mean ± SD) | 4.76 | 0.87 |
CXR score 18 (mean ± SD) | 7.98 | 3.73 |
CXR18 (n, %) | ||
Mild (1–6) | 20 | 39.2% |
Moderate (7–12) | 25 | 49.0% |
Severe (13–18) | 6 | 11.8% |
TSS total score (mean ± SD) | 8.68 | 4.01 |
TSS total score (0–20) (n, %) | ||
None (0) | 1 | 1.9% |
Mild (1–5) | 21 | 41.2% |
Moderate (6–10) | 29 | 56.9% |